HIF-prolyl-4-hydroxylases Inhibitors
1 drugsAbout HIF-prolyl-4-hydroxylases
HIF-prolyl-4-hydroxylases (HIF-PHs) are non-heme iron-containing dioxygenases regulating hypoxia-inducible factors (HIFs), which control cellular response to low oxygen. HIF-PHs hydroxylate HIF-alpha subunits, marking them for degradation under normal oxygen conditions. Inhibiting HIF-PHs stabilizes HIF-alpha, mimicking hypoxia and influencing angiogenesis, erythropoiesis, and glucose metabolism.
HIF-PH inhibition has therapeutic potential by mimicking the cellular response to hypoxia. Currently, there is no genetic evidence directly linking HIF-PHs to specific diseases, but modulation of HIF pathways shows promise. This suggests potential applications in conditions like anemia associated with chronic kidney disease and potentially even cancer.
VAFSEO is the only FDA-approved drug targeting HIF-PHs, with two indications. It is a small molecule drug developed by Akebia, approved in 2024. This represents a new avenue for therapeutic intervention by manipulating the body's natural response to oxygen deprivation.
Top HIF-prolyl-4-hydroxylases Drugs
Akebia is the only company with an approved drug targeting HIF-PHs.
Limited competition provides an opportunity for new entrants, but also indicates potential challenges.
HIF-prolyl-4-hydroxylases Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets HIF-prolyl-4-hydroxylases, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
HIF-prolyl-4-hydroxylases Clinical Trials 29 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on HIF-prolyl-4-hydroxylases. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 9 | 9 | 0 | 0 | 100% |
| Phase 2 | 7 | 5 | 1 | 1 | 83% |
| Phase 3 | 12 | 7 | 3 | 2 | 70% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
HIF-prolyl-4-hydroxylases Drug Approval Timeline (2024 - 2024)
The first drug, VAFSEO, was approved in 2024, marking the beginning of this target class.
Early stage of target class lifecycle suggests high growth potential but also increased regulatory scrutiny.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 6 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on HIF-prolyl-4-hydroxylases. A trial counts if an approved drug acting on HIF-prolyl-4-hydroxylases is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.